Generate Biomedicines Stock: IPO History and Valuation
Biotech / Life Sciences
By UpMarket Research | Last updated: July 2026
CEO George D. YancopoulosFounded 2018HQ Somerville, US
Generate Biomedicines is a biotechnology company using machine learning and biological engineering to design protein-based therapeutics. It focuses on generative biology to create novel medicines for hard-to-drug targets and disease areas including immunology and oncology.
UpMarket does not offer Generate Biomedicines shares. This page covers Generate Biomedicines's history before it went public.
How to Review Generate Biomedicines's Pre-IPO History on UpMarket
Generate Biomedicines became a public company on February 27, 2026 and trades on Nasdaq as GENB. UpMarket does not offer Generate Biomedicines shares. This page covers Generate Biomedicines's valuation and funding history before it went public.
Step 01
Check the listing details
Generate Biomedicines listed on Nasdaq under the ticker GENB on February 27, 2026.
Step 02
Review the valuation history
See how Generate Biomedicines's private-market valuation changed across funding rounds before it went public.
Step 03
Review funding and revenue data
See reported funding rounds and revenue figures on this page, with their sources.
Step 04
Explore private companies
Accredited investors can review UpMarket's current pre-IPO offerings in companies that have not yet gone public.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
${{aum_amount_brokered_en}}B+
UpMarket has brokered over ${{aum_amount_brokered_en}} billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through {{aum_as_of_date_en}}. Of the total, approximately ${{aum_amount_managed_en}} million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.
Valuation Growth Over Time
Post-money valuation by round
Previous roundsMost recent
Date
Round
PPS (split-adj.)
Valuation
Feb 2026
IPO
Sep 14, 2023
Series C
Sep 2023
Series C
$1.8B
Generate Biomedicines Revenue and Growth
Annual revenue
Why Investors Are Watching Generate Biomedicines
Growth Signal
Generate raised $273M Series C to fund 17 programs
Generate:Biomedicines closed a $273 million Series C financing, with investors including Amgen and NVIDIA’s venture arm. The company said the capital will advance 17 existing programs and about 10 new starts per year.
Product Milestone
Platform can recode proteins to keep function, reduce immunity
The Generate Platform says it can completely recode a therapeutic protein to retain function while reducing or eliminating immune recognition. The company describes the system as a continuous build-measure-learn loop designed to accelerate identification and validation of therapeutics.
Market Opportunity
AI drug discovery market cited at $20.6B growing to $41.3B
One industry report cited by MVP VC says the global drug discovery services market was projected to grow from $20.6 billion in 2023 to $41.3 billion. The same report characterizes Generate:Biomedicines as a first-mover in AI-powered drug discovery with low competitive rivalry.
Looking for companies that are still private? Browse UpMarket's pre-IPO company directory. Accredited investors only.
UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
Strategy, fees & legal reviewed in full
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.
Disciplined managers only
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Built around your objectives
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
Yes. Generate Biomedicines became a public company on February 27, 2026 and trades on Nasdaq under the ticker GENB. UpMarket does not offer Generate Biomedicines shares.
Generate Biomedicines's share price is set on the public market under the ticker GENB. The prices shown on this page are historical private-market prices from before it went public.
No. Generate Biomedicines is now a public company and UpMarket does not offer its shares. Accredited investors interested in companies that have not yet gone public can review UpMarket's current pre-IPO offerings.
Generate Biomedicines is now publicly traded, so its shares can be bought and sold on Nasdaq and their price can change significantly. Review Generate Biomedicines's public filings and consult a financial advisor before investing. UpMarket does not offer Generate Biomedicines shares.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
Generate Biomedicines became a public company on February 27, 2026, so shares held before the listing can generally be sold on the public market once any lock-up period ends. The exact terms depend on how the shares are held, for example directly or through a fund.
UpMarket does not offer Generate Biomedicines shares. The minimum for most pre-IPO offerings on UpMarket is $50,000.
Generate Biomedicines's valuation is now set by its public share price on Nasdaq. The figures on this page show its valuation history before it went public.
Generate Biomedicines uses machine learning and biological engineering to design protein-based therapeutics, with $7.2M in 2026 Q1 revenue; it raised a $273M Series C to fund 17 programs. Generate Biomedicines is now a public company, and UpMarket does not offer its shares.